147 related articles for article (PubMed ID: 36587736)
21. Susceptibility of MDR Pseudomonas aeruginosa to ceftolozane/tazobactam and comparison of different susceptibility testing methods.
Schaumburg F; Bletz S; Mellmann A; Becker K; Idelevich EA
J Antimicrob Chemother; 2017 Nov; 72(11):3079-3084. PubMed ID: 28961968
[TBL] [Abstract][Full Text] [Related]
22. Activity of Cefiderocol Against
Iregui A; Khan Z; Landman D; Quale J
Microb Drug Resist; 2020 Jul; 26(7):722-726. PubMed ID: 32031915
[TBL] [Abstract][Full Text] [Related]
23. Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?
Simner PJ; Patel R
J Clin Microbiol; 2020 Dec; 59(1):. PubMed ID: 32727829
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of a Commercial Broth Microdilution Panel for Colistin Susceptibility Testing of Clinical Isolates of Escherichia coli and Klebsiella pneumoniae.
Mirza HC; Bıçakçıgil A; Liste Ü; Sancak B
Clin Lab; 2021 May; 67(5):. PubMed ID: 33978373
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.
Sid Ahmed MA; Abdel Hadi H; Hassan AAI; Abu Jarir S; Al-Maslamani MA; Eltai NO; Dousa KM; Hujer AM; Sultan AA; Soderquist B; Bonomo RA; Ibrahim EB; Jass J; Omrani AS
J Antimicrob Chemother; 2019 Dec; 74(12):3497-3504. PubMed ID: 31504587
[TBL] [Abstract][Full Text] [Related]
27. Real-World Performance of Susceptibility Testing for Ceftolozane/Tazobactam against Non-Carbapenemase-Producing Carbapenem-Resistant Pseudomonas aeruginosa.
Rivas L; Alcalde-Rico M; Martínez JRW; Moreno MV; Rojas P; Wozniak A; García P; Olivares-Pacheco J; Miller WR; Arias CA; Khan A; Munita JM
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0165721. PubMed ID: 34780269
[TBL] [Abstract][Full Text] [Related]
28. Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae.
Ito A; Nishikawa T; Ota M; Ito-Horiyama T; Ishibashi N; Sato T; Tsuji M; Yamano Y
J Antimicrob Chemother; 2018 Nov; 73(11):3049-3052. PubMed ID: 30188999
[TBL] [Abstract][Full Text] [Related]
29. Ceftazidime-avibactam and ceftolozane-tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary.
O'Neall D; Juhász E; Tóth Á; Urbán E; Szabó J; Melegh S; Katona K; Kristóf K
Acta Microbiol Immunol Hung; 2020 Mar; 67(1):61-65. PubMed ID: 32208923
[TBL] [Abstract][Full Text] [Related]
30. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
Pfaller MA; Bassetti M; Duncan LR; Castanheira M
J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526
[TBL] [Abstract][Full Text] [Related]
31. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
Alatoom A; Elsayed H; Lawlor K; AbdelWareth L; El-Lababidi R; Cardona L; Mooty M; Bonilla MF; Nusair A; Mirza I
Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832
[TBL] [Abstract][Full Text] [Related]
32. Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa.
Shields RK; Clancy CJ; Pasculle AW; Press EG; Haidar G; Hao B; Chen L; Kreiswirth BN; Nguyen MH
J Clin Microbiol; 2018 Feb; 56(2):. PubMed ID: 29167294
[TBL] [Abstract][Full Text] [Related]
33. Disc Diffusion and ComASP
Bianco G; Boattini M; Comini S; Banche G; Cavallo R; Costa C
Antibiotics (Basel); 2023 Mar; 12(3):. PubMed ID: 36978470
[TBL] [Abstract][Full Text] [Related]
34. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of three commercial methods of susceptibility testing for ceftolozane/tazobactam against carbapenem-resistant Pseudomonas aeruginosa.
López-Cerero L; Ballesta S; López CE; Sánchez-Yebra W; Rojo-Martin MD; Pascual A
Enferm Infecc Microbiol Clin (Engl Ed); 2023 Dec; 41(10):621-624. PubMed ID: 36737371
[TBL] [Abstract][Full Text] [Related]
36. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
Sader HS; Farrell DJ; Flamm RK; Jones RN
J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
[TBL] [Abstract][Full Text] [Related]
37. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
Jones RN; Barry AL; Thornsberry C; Gerlach EH; Fuchs PC; Gavan TL; Sommers HM
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
[TBL] [Abstract][Full Text] [Related]
38. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
Henderson A; Tan E; McCarthy KL; Paterson DL
Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Agar Dilution to Broth Microdilution for Testing
Albano M; Karau MJ; Schuetz AN; Patel R
J Clin Microbiol; 2020 Dec; 59(1):. PubMed ID: 32967901
[TBL] [Abstract][Full Text] [Related]
40. Multicenter Evaluation of the Etest Gradient Diffusion Method for Ceftolozane-Tazobactam Susceptibility Testing of Enterobacteriaceae and Pseudomonas aeruginosa.
Bailey AL; Armstrong T; Dwivedi HP; Denys GA; Hindler J; Campeau S; Traczewski M; Humphries R; Burnham CA
J Clin Microbiol; 2018 Sep; 56(9):. PubMed ID: 29976590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
